1 Min Read The Future of Immunotherapy
July 24, 2026Core Framework & Diagram The Future of Immunotherapy
July 24, 2026From 'activating immunity' to 'precisely orchestrating immunity' — five paradigm shifts in next-generation immunotherapy
—— The future of immunotherapy: not just better drugs, but a more complete therapeutic philosophy.
I. From late-stage treatment to early prevention: fundamental change in the timeline
Existing immunotherapy is mostly started after cancer is already diagnosed — often in middle to late stages. This timeline has a fundamental disadvantage: the tumor has already established quite complete immune escape mechanisms and microenvironmental barriers. Next-generation immunotherapy's most important timing shift is moving to earlier stages: adjuvant/neoadjuvant treatment stage — after surgical tumor resection (adjuvant) or before (neoadjuvant), using immunotherapy to clear residual micrometastases, establish durable immune memory, prevent recurrence. mRNA-4157's Phase 2 trial was used precisely in the adjuvant stage after melanoma surgical resection — one of the most valuable time windows, because tumor burden is lowest and the immune system has maximum advantage. Pre-cancer/high-risk stage — for populations with clearly high-risk characteristics (BRCA mutation carriers, MGUS/Smoldering Myeloma, colorectal cancer high-risk individuals already with adenoma), intervening with immunotherapy before cancer occurs is the theoretically most efficient intervention point.
Liquid biopsy-guided ultra-early intervention — when circulating tumor DNA (ctDNA) detection sensitivity is high enough to detect tumor signals months before imaging-visible tumors, this will provide a completely new intervention timing for immunotherapy: at the stage when the tumor has only thousands of cells and the immune system has almost overwhelming advantage. The timeline's advancement represents a fundamental shift in medical philosophy: from 'discover disease then treat,' to 'foresee risk and intervene at the most advantageous timing.'
2. Multimodal combination: from fighting alone to collaborative combat
Early immunotherapy had an implicit expectation: find 'that key molecule,' open it, and cancer will be controlled. When PD-1 was discovered, many people held this expectation. Reality is more complex. Single PD-1 inhibitors, in the best solid tumor indications, have response rates of only twenty to forty percent. Even responding patients often develop resistance within one to two years. Next-generation immunotherapy's mainstream paradigm is multimodal systemic combination: immune activation + checkpoint release: individualized neoantigen vaccines (activating tumor-specific T cells) + PD-1 inhibitors (removing T cell blockade) — currently the most promising synergistic combination; cell therapy + checkpoint release: CAR-T/CAR-NK (providing high-activity effector cells) + PD-1 inhibitors (preventing these cells from being shut down in TME); microenvironment remodeling + cell therapy: oncolytic viruses or STING agonists (warming cold tumors) + CAR-T or NK cell therapy (achieving greater effectiveness in an already-activated microenvironment); radiation + immunity: local radiation (activating tumor's 'immunogenic death,' releasing tumor antigens) + systemic checkpoint inhibitors (activating whole-body anti-tumor immune responses, achieving 'abscopal effect' — local radiation, systemic anti-tumor); nano delivery + gene editing + cell therapy: in vivo CAR-T (LNP targeting T cells for gene editing) + microenvironment remodeling (CAF targeting) + checkpoint inhibitors.
|
Immunotherapy's future is a symphony, not a solo. Each intervention is an instrument — with its own voice and rhythm, and only when all instruments play in concert is the most moving effect produced. |
3. Precise orchestration: not just activating, but controlling 'when to stop'
Immunotherapy's most dangerous side effects are often not because it failed, but because it succeeded too well — the immune system becomes over-activated, beginning to attack normal tissue (immune-related adverse events, irAE). Next-generation immunotherapy, while pursuing stronger effects, is also increasingly focused on 'precise control' — what cells, where, doing what, to what degree, then stopping. Technical directions: local delivery (like intratumoral injection) — limiting immune activation effects to the tumor area, reducing systemic toxicity; conditional activation (like SynNotch) — T cells only activate when two tumor signals are simultaneously present, reducing normal tissue misfiring; safety switch design (like iCasp9) — built-in 'emergency stop' mechanisms in cell therapy, enabling shutdown of engineered cells when severe irAE appears; immune regulatory combination (like anti-inflammatory drugs + immunotherapy) — while launching immune attacks, preventively controlling inflammatory overcascading.
The 'precise orchestration' vision is a precisely controllable immunotherapy system: activating when needed, winding down when task is completed, emergency braking when risks appear, restarting when needed again. This approaches treating the immune system as a precisely drivable tool, not just a natural force that can only be released or braked.
4. From high-cost customization to scalable precision: accessibility revolution
Current immunotherapy's biggest obstacle is cost and accessibility. One course of CAR-T in the United States costs $300,000–500,000, beyond most patients' payment capacity. Individualized mRNA vaccine manufacturing currently still requires weeks and huge fees. Next-generation immunotherapy's accessibility revolution will advance on several paths: Universal cell therapy (Off-the-Shelf) — universal CAR-NK and CRISPR universal CAR-T, changing 'manufacturing individually for each patient' to 'manufacture once, supply everyone,' costs can decrease more than ten times; In vivo CAR-T — LNP directly modifying T cells in body, completely eliminating the ex vivo manufacturing process and cost, theoretically reducing cost from hundreds of thousands of dollars to potentially thousands; mRNA vaccine platform scale effects — as mRNA manufacturing technology matures and automates, individualized vaccine synthesis time and cost will rapidly decrease; Asian local manufacturing — China, Korea, India and other countries are rapidly building local cell therapy and mRNA technology manufacturing capabilities, local production will greatly reduce dependence on imported products and costs.
5. Immunotherapy and chronic diseases: beyond cancer's boundaries
Immunotherapy's future isn't only cancer. Checkpoint inhibitors' success has inspired researchers to apply similar 'regulating immune brakes/accelerators' logic to autoimmune diseases, neurodegenerative diseases, metabolic diseases, and aging: autoimmune disease precision immune regulation — using logic similar to checkpoint inhibitors, but reverse: targeting activation of 'brake mechanisms' (Treg pathways, IL-10, low-dose IL-2), rather than releasing brakes. In SLE, RA, MS, and Type 1 diabetes clinical trials, increasingly more precision immune regulation regimens are showing signals; neurodegenerative diseases — Alzheimer's disease's microglial activation is increasingly recognized as the disease's core mechanism, not just an accompanying phenomenon. Targeting microglial activation (TREM2 agonists, CSF-1R inhibitors) immunotherapy is advancing in clinical trials; metabolic immunotherapy — targeting abnormal immune activation in inflammatory obesity and Type 2 diabetes (pro-inflammatory adipokines from visceral fat, immune damage to islet β cells), using immune regulatory means to improve metabolic diseases.
Frequently Asked Questions